Skip to main content
Premium Trial:

Request an Annual Quote

Inverness to Distribute Molecular Detection's MRSA Assay

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Inverness Medical Deutschland has gained exclusive rights to distribute Molecular Detection's Detect-Ready MRSA assay in Germany, Austria, and Switzerland, the firms announced today.

Molecular Detection's assay is a real-time PCR in vitro diagnostic test for direct detection of methicillin-resistant Staphylococcus aureus nasal colonization to aid in the prevention and control of MRSA infections in hospitals and other health care settings. The Wayne, Pa.-based firm said that the Detect-Ready kits require no special handling and are off-the-shelf, room-temperature stabilized, and require no refrigeration. It add that the kits are compatible with multiple rt-PCR platforms, including Roche's LightCycler, Qiagen's Rotor-Gene, and Cepheid's SmartCycler.

Cepheid sells its own MRSA assays for use on its platform in clinical settings, while Qiagen sells the StaphPlex Panel, which can detect MRSA DNA for research applications.

"Germany is taking a leadership role in combating the spread of MRSA infections, and Austria and Switzerland are also initiating proactive MRSA control programs," Dave Sieber, managing director of Inverness Medical Deutschland, said in a statement. "With its unmatched combination of accuracy, speed, versatility and cost effectiveness, we believe the Detect-Ready MRSA assay can contribute to the success of these efforts."

Molecular Detection noted that the Detect-Ready MRSA assay kit has received CE mark certification for sales in the European Union.